
    
      This is a randomized, double-blind, placebo-controlled study to assess the safety,
      tolerability and potential cognitive benefit of GRF6019, a human plasma protein fraction.
      GRF6019 or placebo will be administered intravenously to subjects with severe Alzheimer's
      disease every day for 5 consecutive days. The total study duration for each subject is
      approximately 9 weeks.
    
  